495 related articles for article (PubMed ID: 20100483)
41. Adenovirus-mediated overexpression of p15INK4B inhibits human glioma cell growth, induces replicative senescence, and inhibits telomerase activity similarly to p16INK4A.
Fuxe J; Akusjärvi G; Goike HM; Roos G; Collins VP; Pettersson RF
Cell Growth Differ; 2000 Jul; 11(7):373-84. PubMed ID: 10939591
[TBL] [Abstract][Full Text] [Related]
42. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro.
Finn RS; Dering J; Conklin D; Kalous O; Cohen DJ; Desai AJ; Ginther C; Atefi M; Chen I; Fowst C; Los G; Slamon DJ
Breast Cancer Res; 2009; 11(5):R77. PubMed ID: 19874578
[TBL] [Abstract][Full Text] [Related]
43. RB loss abrogates cell cycle control and genome integrity to promote liver tumorigenesis.
Mayhew CN; Carter SL; Fox SR; Sexton CR; Reed CA; Srinivasan SV; Liu X; Wikenheiser-Brokamp K; Boivin GP; Lee JS; Aronow BJ; Thorgeirsson SS; Knudsen ES
Gastroenterology; 2007 Sep; 133(3):976-84. PubMed ID: 17854601
[TBL] [Abstract][Full Text] [Related]
44. Dual cyclin-dependent kinase 4/6 inhibition by PD-0332991 induces apoptosis and senescence in oesophageal squamous cell carcinoma cells.
Chen L; Pan J
Br J Pharmacol; 2017 Aug; 174(15):2427-2443. PubMed ID: 28444744
[TBL] [Abstract][Full Text] [Related]
45. Rb and E2F-1 regulate telomerase activity in human cancer cells.
Crowe DL; Nguyen DC
Biochim Biophys Acta; 2001 Mar; 1518(1-2):1-6. PubMed ID: 11267653
[TBL] [Abstract][Full Text] [Related]
46. Combined Blockade of MEK and CDK4/6 Pathways Induces Senescence to Improve Survival in Pancreatic Ductal Adenocarcinoma.
Willobee BA; Gaidarski AA; Dosch AR; Castellanos JA; Dai X; Mehra S; Messaggio F; Srinivasan S; VanSaun MN; Nagathihalli NS; Merchant NB
Mol Cancer Ther; 2021 Jul; 20(7):1246-1256. PubMed ID: 34001634
[TBL] [Abstract][Full Text] [Related]
47. Combining CDK4/6 inhibition with taxanes enhances anti-tumor efficacy by sustained impairment of pRB-E2F pathways in squamous cell lung cancer.
Cao J; Zhu Z; Wang H; Nichols TC; Lui GYL; Deng S; Rejto PA; VanArsdale T; Hardwick JS; Weinrich SL; Wei P
Oncogene; 2019 May; 38(21):4125-4141. PubMed ID: 30700828
[TBL] [Abstract][Full Text] [Related]
48. The retinoblastoma gene product inhibits TGF-beta1 induced apoptosis in primary rat hepatocytes and human HuH-7 hepatoma cells.
Fan G; Ma X; Kren BT; Steer CJ
Oncogene; 1996 May; 12(9):1909-19. PubMed ID: 8649852
[TBL] [Abstract][Full Text] [Related]
49. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
50. Targeting cell cycle and hormone receptor pathways in cancer.
Comstock CE; Augello MA; Goodwin JF; de Leeuw R; Schiewer MJ; Ostrander WF; Burkhart RA; McClendon AK; McCue PA; Trabulsi EJ; Lallas CD; Gomella LG; Centenera MM; Brody JR; Butler LM; Tilley WD; Knudsen KE
Oncogene; 2013 Nov; 32(48):5481-91. PubMed ID: 23708653
[TBL] [Abstract][Full Text] [Related]
51. Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.
Green JL; Okerberg ES; Sejd J; Palafox M; Monserrat L; Alemayehu S; Wu J; Sykes M; Aban A; Serra V; Nomanbhoy T
Mol Cancer Ther; 2019 Apr; 18(4):771-779. PubMed ID: 30837298
[TBL] [Abstract][Full Text] [Related]
52. Therapeutic Challenge with a CDK 4/6 Inhibitor Induces an RB-Dependent SMAC-Mediated Apoptotic Response in Non-Small Cell Lung Cancer.
Thangavel C; Boopathi E; Liu Y; McNair C; Haber A; Perepelyuk M; Bhardwaj A; Addya S; Ertel A; Shoyele S; Birbe R; Salvino JM; Dicker AP; Knudsen KE; Den RB
Clin Cancer Res; 2018 Mar; 24(6):1402-1414. PubMed ID: 29311118
[No Abstract] [Full Text] [Related]
53. Preclinical Activity of Ribociclib in Squamous Cell Carcinoma of the Head and Neck.
van Caloen G; Schmitz S; El Baroudi M; Caignet X; Pyr Dit Ruys S; Roger PP; Vertommen D; Machiels JP
Mol Cancer Ther; 2020 Mar; 19(3):777-789. PubMed ID: 31924739
[TBL] [Abstract][Full Text] [Related]
54. PROTAC-mediated CDK degradation differentially impacts cancer cell cycles due to heterogeneity in kinase dependencies.
Kumarasamy V; Gao Z; Zhao B; Jiang B; Rubin SM; Burgess K; Witkiewicz AK; Knudsen ES
Br J Cancer; 2023 Oct; 129(8):1238-1250. PubMed ID: 37626264
[TBL] [Abstract][Full Text] [Related]
55. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
56. Dual Inhibition of CDK4/6 and XPO1 Induces Senescence With Acquired Vulnerability to CRBN-Based PROTAC Drugs.
Wang H; Yuan S; Zheng Q; Zhang S; Zhang Q; Ji S; Wang W; Cao Y; Guo Y; Yang X; Geng H; Yang F; Xi S; Jin G; Zhang J; Gao Q; Bernards R; Qin W; Wang C
Gastroenterology; 2024 Jun; 166(6):1130-1144.e8. PubMed ID: 38262581
[TBL] [Abstract][Full Text] [Related]
57. Modification of the DNA damage response by therapeutic CDK4/6 inhibition.
Dean JL; McClendon AK; Knudsen ES
J Biol Chem; 2012 Aug; 287(34):29075-87. PubMed ID: 22733811
[TBL] [Abstract][Full Text] [Related]
58. Therapeutic response to CDK4/6 inhibition in breast cancer defined by ex vivo analyses of human tumors.
Dean JL; McClendon AK; Hickey TE; Butler LM; Tilley WD; Witkiewicz AK; Knudsen ES
Cell Cycle; 2012 Jul; 11(14):2756-61. PubMed ID: 22767154
[TBL] [Abstract][Full Text] [Related]
59. Selective CDK4/6 inhibition of novel 1,2,3-triazole tethered acridinedione derivatives induces G1/S cell cycle transition arrest via Rb phosphorylation blockade in breast cancer models.
Praveenkumar E; Gurrapu N; Kolluri PK; Shivaraj ; Subhashini NJP; Dokala A
Bioorg Chem; 2021 Nov; 116():105377. PubMed ID: 34670329
[TBL] [Abstract][Full Text] [Related]
60. A selective cyclin-dependent kinase 4, 6 dual inhibitor, Ribociclib (LEE011) inhibits cell proliferation and induces apoptosis in aggressive thyroid cancer.
Lee HJ; Lee WK; Kang CW; Ku CR; Cho YH; Lee EJ
Cancer Lett; 2018 Mar; 417():131-140. PubMed ID: 29306020
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
